Nuvilex Inc. Reminiscent of Major Biotech Success Stories

Nuvilex Inc. Reminiscent of Major Biotech Success Stories 
BALTIMORE, MD -- (Marketwired) -- 05/14/13 --  Goldman Small Cap
Research, a stock market research firm focused on the small cap and
micro cap sectors, notes that the current positioning of Nuvilex Inc.
(OTCQB: NVLX) and its proprietary live-cell encapsulation platform
delivery system is reminiscent of some of the greatest biotechnology
success stories of the past 20 years. Some of the companies that come
to mind are Genentech (the "original" biotech) which was acquired by
Roche, Inc., Amgen, Inc., and Celgene Corp. 
Genentech, which has a major focus on oncology treatments, has some
of the largest selling oncology drugs in its arsenal, generating
around $12 billion in annual sales alone for the company. It is the
success of its platform technology that resulted in its $47 billion
acquisition in 2009. Clearly, its broad success in oncology, notably
treating pancreatic cancer and breast cancer, which sit atop the
Nuvilex (OTCQB: NVLX) to-do list, indicate the huge value the market
places on oncology treatment success.  
Amgen, the world's largest biotech company with a $78 billion market
cap, has grown in part through acquisition and collaborations with
many other pharmaceutical firms. The Nuvilex (OTCQB: NVLX) platform
delivery system could emerge as an agnostic and broadly used system
that is licensed to other firms, for use in their own clinical trials
and studies. 
The Celgene acquisition of Abraxas Bioscience for $2.9 billion in
2010 appears to be a path that many investors could envision for
Nuvilex (OTCQB: NVLX). Abraxas, which was noted for its proprietary
tumor targeting technology, was acquired after receiving FDA approval
for its lead product to treat breast cancer.  
When looking at these leaders, it is clear that collaborations,
strategic investments and potential M&A could occur once the Company
has an approval in its quiver and other mid-late stage trials,
ongoing.  
To view a summary of Nuvilex reports or download the reports in their
entirety, please visit www.goldmanresearch.com 
About Goldman Small Cap Research: Led by former Piper Jaffray analyst
and mutual fund manager Rob Goldman, Goldman Small Cap Research
produces small cap and micro cap stock research reports, daily stock
market blogs, and popular investment newsletters. For more
information, visit www.goldmanresearch.com. 
A Goldman Small Cap Research report is not intended as an offering,
recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed. Please read the report's full
disclosures and analyst background on our website before investing.
Neither Goldman Small Cap Research nor its parent is a registered
investment adviser or broker-dealer with FINRA or any other agency.
To download our research, view our disclosures, or for more
information, visit www.goldmanresearch.com. 
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider
of all-natural products for many years, has expanded its company to
increase its natural product based footprint through medical
marijuana studies and is becoming an international biotechnology
provider of live, therapeutically valuable, encapsulated cells and
services for treatments, research and medicine. The Company's
offerings will ultimately include cancer, diabetes and other clinical
treatments using the company's natural product knowledge, product
base, cell and gene therapy expertise, and live-cell encapsulation
technology in addition to other new products currently under
development. For more information visit: www.nuvilex.com. 
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com